ID: MRFR/HC/6985-HCR | February 2021 | Region: Global | 125 pages
Uveitis Treatment Market is Expected to cross USD 764.5 Million by 2025 at a CAGR of 5.6%.
Uveitis is a form of inflammation that occurs in the middle layer of the eyeball known as the uvea. It is accompanied by symptoms such as pain, redness of the eyes, and blurred vision. It mainly occurs in people aged between 20 to 50 years. There are three main types of uveitis—anterior uveitis, posterior uveitis, and intermediate uveitis.
For instance, in June 2016, AbbVie Inc received FDA (Food and Drug Administration) approvals for its HUMIRA in the treatment of non-infectious intermediate, posterior, and panuveitis. This helped it to strengthen its uveitis treatment product portfolio.
Rising prevalence of uveitis, increasing R&D expenditure, and product launches are likely to impact the growth of the uveitis treatment industry positively.
Increased R&D expenditure in the healthcare industry will support the growth of the uveitis treatment market.
The growth of the market is driven by the increasing number of product launches in the global uveitis treatment market. For example, in October 2018, EyePoint Pharmaceuticals received FDA approval for Yutiq (fluocinolone acetonide intravitreal implant). This product is used in the treatment of chronic non-infectious uveitis.
Increasing prevalence of the uveitis across the globe
Anterior Uveitis: In anterior uveitis, inflammation forms in the middle layer of the eye that includes the iris and adjacent tissue. This segment holds the most significant share in the type segment. Mainly topical drops such as corticosteroid drops are prescribed by the physician in the treatment of the anterior uveitis.
Intermediate Uveitis: It occurs in children as well as young adults. It accounts for 2% 31% of all uveitis patients and incidence of the intermediate uveitis between 1.4% to 2% in Germany.
Posterior Uveitis: In posterior uveitis, the inflammation primarily forms in the retina and choroid area of the eye.
By Drug Class
Corticosteroids Drugs: This drug class is most commonly used for the treatment of uveitis. It expected to hold the largest share in the global market due to the increasing preference of this drug class and desirable outcomes. Major corticosteroid brands in the market are Ozurdex (Allergan PLC) and Triesence suspension (Novartis AG).
Anti-Inflammatory Drugs: In chronic uveitis, non-steroid anti-inflammatory drugs are used to treat inflammation over a more extended period.
Immunosuppressive Drugs: Maximum immunosuppressive agents have significant adverse effects due to which these drugs are not used very often for the treatment of the uveitis.
Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals. In 2018, the hospital's segment held the largest share of the market.
Specialty Clinics: Consisting of long-term care for chronic patients and the elderly, this is a fast-growing market segment, especially in developed nations.
Americas: The Americas held the largest regional market in 2018. The US has over 7,200 active hospitals and a well-established healthcare sector. This serves to drive development in the region's market for uveitis treatment.
Additionally, increasing the incidence of uveitis in the US is likely to support the growth of the market. The annual rate of uveitis around 26.6 to 102 per 100,000 adults in the US. Moreover, uveitis has led to about 2.8% of cases of blindness in the US.
Europe: The need for uveitis treatment is high in this region due to the rising prevalence of the uveitis in the region.
Asia-Pacific: The Asia-Pacific is the fastest-growing region for the uveitis treatment market. It has the world’s largest population and a fast-developing healthcare sector.
Middle East & Africa: It is projected to account for the least share of the global market due to low per capita disposable incomes in the region and limited development of healthcare facilities.
Frequently Asked Questions (FAQ) :
The valuation of the global uveitis treatment market is estimated to reach USD 764.5 MN by 2025.
The global uveitis treatment market is projected to grow at approximately 5.6% CAGR during the forecast period (2019-2025).
Increasing numbers of product launches.
North America holds the largest share in the global uveitis treatment market, followed by Europe and the Asia Pacific, respectively.
Novartis AG (Switzerland), Allergan PLC (Ireland), Bausch Health (Canada), AbbVie Inc. (US), EyePoint Pharmaceuticals, Inc. (US), Horizon Therapeutics Plc (Ireland), Alimera Sciences (US), and Mylan NV (US), are some of the major players operating in the uveitis treatment market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.